US5324571083
US5324571083
Eli Lilly and Company
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.05T EUR | 1.07T EUR | 821.81B EUR | 961.62B EUR |
Enterprise Value | 1.09T EUR | 1.12T EUR | 859.9B EUR | 996.86B EUR |
Valuation Multiples | ||||
Trailing P/E | 39.59x | 40.03x | 32.51x | 53.78x |
Forward P/E | 24.78x | -- | -- | -- |
Price to Sales | 13.19x | 13.42x | 11.37x | 18.33x |
Price to Book | 31.03x | 31.56x | 26.34x | 36.24x |
EV/Revenue | 13.66x | 14x | 11.9x | 19.01x |
EV/EBITDA | 26.1x | 22.65x | 21.27x | 34.05x |
Price to FCF (P/FCF) | 94.99x | 78.86x | 79.26x | 127.11x |
EV/FCF | 98.36x | 82.25x | 82.94x | 131.77x |
FCF Yield | 1.05% | 1.27% | 1.26% | 0.79% |